Year: 2019

BerGenBio to Present at H.C. Wainwright Global Life Sciences Conference

April 9, 2019

Bergen, Norway, April 09 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on developing…

Read More

BerGenBio extends Phase II trial with bemcentinib and KEYTRUDA® in NSCLC to include patients with disease progression on immune checkpoint inhibitor therapy

April 2, 2019

Bergen, Norway, 2 April 2019 – BerGenBio ASA (OSE: BGBIO) announces that the first patient…

Read More

BerGenBio: Preclinical data presented at AACR reinforces bemcentinib’s potential to reverse tumour immunosuppression and therapy resistance

April 2, 2019

Extensive data in pre-clinical models of non-small cell lung cancer (NSCLC) and pancreatic cancer demonstrating…

Read More

BerGenBio: Bemcentinib in combination with low-dose chemotherapy achieves efficacy endpoint in AML patients

April 1, 2019

Phase II trial evaluating bemcentinib in combination with low-dose chemotherapy in AML patients unfit for…

Read More

BerGenBio ASA publishes Annual Report for 2018

February 20, 2019

Bergen, Norway, 20 February 2019 – The Board of Directors of BerGenBio ASA (OSE:BGBIO) has…

Read More

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

February 12, 2019

Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and…

Read More